FDA/CDC

FDA authorizes first direct-to-consumer BRCA1/2 test


 

The Food and Drug Administration has authorized the first direct-to-consumer (DTC) test to report on three specific BRCA1/BRCA2 breast cancer gene mutations.

Personal Genome Service Genetic Health Risk (GHR) Report for BRCA1/BRCA2 (Selected Variants) does not identify the most common BRCA1/2 mutations but rather the three most common in people of Ashkenazi (Eastern European) Jewish descent, the FDA said in a press statement.


The test, marketed by 23andMe, analyzes DNA from a self-collected saliva sample.

The three mutations identified by the test are present in about 2% of Ashkenazi Jewish women, but rarely in other ethnic populations. Any individual who takes the test may have other mutations in BRCA1 or BRCA2 genes, or other cancer-related gene mutations that are not detected by this test.

Pages

Recommended Reading

Half of all breast cancer survivors conceived naturally within 3 months of trying
MDedge Family Medicine
Shaping practice: Z1071 continues to redefine axillary management
MDedge Family Medicine
VIDEO: Weight loss cut risk of breast cancer
MDedge Family Medicine
Extra years of adjuvant bisphosphonate not needed in early breast cancer
MDedge Family Medicine
Postmenopausal women who shed pounds see lower breast cancer risk
MDedge Family Medicine
POSH study: BRCA mutations did not influence survival in young onset breast cancer
MDedge Family Medicine
New multi-analyte blood test shows promise in screening for several common solid tumors
MDedge Family Medicine
STUDY: More mammograms after cost-sharing elimination
MDedge Family Medicine
AHA: Heart health helps optimize breast cancer outcomes
MDedge Family Medicine
Breast cancer deaths projected for 2018
MDedge Family Medicine